AI and Big Data in Agritech

No items found.
​
March 28, 2024

First published by Process Engineering - February 2024

The world's population stands above 8 billion in 2024 and is still growing. That growth may be slowing down but nonetheless there may be another 2 billion mouths to feed in the next 50 years. Furthermore, it is predicted that the expected improvements in crop yields in that same time frame will be offset by increased disease pressure resulting from climate change.

The agricultural industry is increasingly turning to data-driven approaches to give them every advantage. What are researchers doing to take advantage of computers in the crop research and agritech space?

Bioinformatics

Computational genomics and other aspects of bioinformatics are incredibly important in understanding plant genomes. Typically plant research is performed on Arabidopsis thaliana, a model organism with only a small diploid genome of around 135 million base pairs which makes genetic analysis more straightforward. Unfortunately, crop plants tend to have much larger and more complex genomes. Bread wheat has a hexaploid genome of around 17 billion base pairs. Furthermore, the high percentage (close to 80%) of repetitive sequences makes gene sequence analysis more difficult. By comparison, about 50% of the human genome is repetitive sequences and that is on the higher side for mammals, let alone other eukaryotes. As such, developing new varieties and new transgenic crop plants can be very difficult.

This difficulty is enhanced in jurisdictions such as the EU where GMO crops are not authorised for human consumption; so bioinformatics techniques have to be used to enhance conventional crop breeding techniques rather than making direct modifications of the plant genome. Elsewhere, though there are sign of change: the UK passed the Genetic Technology (Precision Breeding) Act for England last year – reducing the regulatory burden breeders face when making genetic modifications that could have occurred naturally through conventional breeding, but not introducing exogenous genes from other species. Similar legislation is being considered in the EU.

Microbiome analysis is also a big part of the bioinformatics space. Rothamsted Research recently received a £4 million award for new computer infrastructure which will help analyse soil metagenomics, essential for understanding the soil in greater details as many of the microbes in soil cannot be readily cultivated in a lab.

Considering the patent side, we can see that many of the applications filed relate to the application of machine learning approaches to genomics or disease detection. We also see filings for prediction systems to optimise the chances of breeding success based on genomic data, whether via AI techniques or more classical statistical methods. Analysis of pathogens is common, with looking for pathogen DNA or identifying pesticide resistance genes.

Crop Modelling

Crop modelling continues to improve and develop, as it has for decades, but there are issues with lack of open data. Crop simulation has been developed since the 1960s but a renewed interest in the field has arisen from the improved sources of data (such as from remote sensing), the increasing demand from population growth, the impact of climate change, and the application of machine learning.

Looking at patent filings, development of these technologies seem to be in the application of machine learning but nonetheless, we still see filings for improvements to more classical state machines.

Interestingly, the majority of filings are in China and the US. The former is to be expected given the domestic patent policy in China but it is a little surprising to see hardly any PCT 1.applications being taken forward in Europe. This may be due to the understanding of the European Patent Office's requirements that computer software must have a technical effect in order to be patentable. As such, more abstract processes are less likely to be patentable in Europe. However, it should be understood that simulation can definitely be patented in Europe with the right claim wording, provided of course the invention has an inventive step and meets the other patentability criteria.

Remote Sensing

Remote Sensing generally refers to the collection of information about something from a distance but typically refers to the usage of Earth observation satellites and camera drones. Some satellites are government-owned such as the European Space Agency's Sentinel satellites. Others are owned by private enterprise, such as Airbus's Pleiades Neo satellites.

Remote sensing from satellites has been used for decades to measure crop productivity. It has also been employed to detect and map plant diseases, which often alter the appearance and structure of the plants in such a way that is detectable through multispectral data; for example from yellowing leaves or from wilting crops altering the angular polarisation of radar scans.

Satellite technologies are also relevant to livestock monitoring. Albeit satellites are less effective at this given animals tendency to wander more than plants and because most satellites only pass over the same point at most a couple of times per day as the Earth rotates.

Great strides are also being made with aerial photography and the integration of that with satellite remote sensing. The massive proliferation of drone technology and improvement in digital camera technology allows farmers to survey huge areas with a high degree of accuracy. Drone footage not only provides a ground truth for human verification but can also be used more generally as a data source to integrate a big data approach.

Increasingly, we can expect a democratisation of this technology to smaller and smaller farmers, particularly as nearly all of the data captured by the Copernicus satellite constellation is freely available to download on the internet.

The number of patent applications filed for space-borne sensing and green applications has been rising rapidly in recent years, as shown in an EPO, ESA, ESPI joint study released in October 2022. The main developments that are being filed for are in signal processing on the software side, and AI/ML seems to be the core driver for this. Analysis and modelling of photosynthetic activity and crop productivity are also frequently mentioned in these applications, as well as weather and river/coastal observations.

In summary, agritech has always been an area of significant technological advancement but data driven technologies are becoming increasingly relevant in our interconnected world.

1. Patent Cooperation Treaty or ‘international' patent applications offer simultaneous protection in a number of signatory states

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​